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Deficiency of α-galactosidase A (α-GAL) causes Fabry disease (FD), an X-linked storage
disease of the glycosphingolipid globtriaosylcerammide (Gb3) in lysosomes of various
cells and elevated plasma globotriaosylsphingosine (Lyso-Gb3) toxic for podocytes and
nociceptive neurons. Enzyme replacement therapy is used to treat the disease, but
clinical efficacy is limited in many male FD patients due to development of neutralizing
antibodies (Ab). Therapeutic use of modified lysosomal α-N-acetyl-galactosaminidase
(α-NAGAL) with increased α-galactosidase activity (α-NAGALEL) has therefore been
suggested. We transiently produced in Nicotiana benthamiana leaves functional α-GAL,
α-NAGAL, and α-NAGALEL enzymes for research purposes. All enzymes could be
visualized with activity-based probes covalently binding in their catalytic pocket.
Characterization of purified proteins indicated that α-NAGALEL is improved in activity
toward artificial 4MU-α-galactopyranoside. Recombinant α-NAGALEL and α-NAGAL
are not neutralized by Ab-positive FD serum tested and are more stable in human
plasma than α-GAL. Both enzymes hydrolyze the lipid substrates Gb3 and Lyso-Gb3
accumulating in Fabry patients. The addition to FD sera of α-NAGALEL, and to a lesser
extent that of α-NAGAL, results in a reduction of the toxic Lyso-Gb3. In conclusion,
our study suggests that modified α-NAGALEL might reduce excessive Lyso-Gb3 in FD
serum. This neo-enzyme can be produced in Nicotiana benthamiana and might be
further developed for the treatment of FD aiming at reduction of circulating Lyso-Gb3.
Keywords: α-galactosidase, α-N-acetyl-galactosaminidase, Fabry disease, therapy, recombinant enzyme,
Nicotiana benthamiana
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INTRODUCTION
Deficiencies in lysosomal enzymes are the cause of various
inherited lysosomal storage disorders in humans (Futerman and
Van Meer, 2004). Examples are Gaucher disease (GD), Pompe
disease and Fabry disease (FD) with deficiencies of acid beta-
glucosidase (glucocerebrosidase, GBA), acid alpha-glucosidase
and acid alpha-galactosidase (α-GAL) respectively. For each of
these diseases, enzyme replacement therapy (ERT) approaches
have been designed and are applied with variable success.
Highly efficient is ERT for GD resulting in reversal and/or
prevention of organomegaly and hematological abnormalities in
non-neuropathic type 1 patients (Barton et al., 1990). ERT of
Pompe disease has been shown to increase the life expectancy
in patients suffering from the infantile form of the disorder
(Van den Hout et al., 2000). Two similar approaches were also
developed for FD using human α-GAL produced in Chinese
hamster ovary cells (agalsidase beta; FabrazymeTM; Sanofi-
Genzyme) or human fibroblasts (agalsidase alfa; ReplagalTM;
Shire) (Eng et al., 2001; Schiffmann et al., 2001). Both enzyme
preparations were registered in August 2001 as orphan drug
in Europe, but only Fabrazyme was approved by the FDA in
the United States (Desnick, 2004). Fabrazyme and Replagal
are infused bi-weekly at a dose of 1.0 and 0.2 mg/kg body
weight, respectively (Eng et al., 2001; Schiffmann et al.,
2001).
α-Galactosidase A (α-GAL; E.C. 3.2.1.22) is encoded by the
GLA (ID: 2717) gene at locus Xq22 (Desnick et al., 2001).
The enzyme is synthesized as 429 amino acid precursor from
which the signal peptide is removed to yield a 398 amino
acid glycoprotein forming a homodimer (Brady et al., 1967;
Hamers et al., 1977; Bishop et al., 1988; Desnick et al.,
2001). Formation of mannose-6-moieties (M6P) in the 3
N-linked glycans of α-GAL allows transport to lysosomes by
mannose-6-phosphate receptors (M6PR) (Sakuraba et al., 2005).
The natural substrates of α-GAL are glycosphingolipids with
terminal α-galactosyl moieties, including globotriaosylceramide
(Gb3; ceramidetrihexoside: CTH), galabiosylceramide, and blood
group B, B1, and P1 antigens (Sweeley and Klionsky, 1963;
Desnick et al., 1996). In various cell types of classic male
FD patients Gb3 accumulates in intra-lysosomal lipid deposits.
Both Fabrazyme and Replagal are aimed to be delivered to
lysosomes of cells by M6PR mediated endocytosis (Sakuraba
et al., 2005). Unfortunately, the evaluation of long-term ERT
of FD patients indicates that clinical efficacy is relatively poor
(Schuller et al., 2015). ERT treatments result in the case of
some FD patients in stabilization of disease, but progression
of symptoms has also been observed (Blom et al., 2003; Lin
et al., 2009). The poor response to ERT of classic FD males,
usually completely lacking α-GAL protein, is partially explained
by the common induction in these individuals of neutralizing
antibodies (Ab) against the therapeutic enzyme (Linthorst et al.,
2004).
A recent important insight on pathogenesis of FD stems
from the notion that the storage lipid Gb3 is partly actively
converted to its sphingoid base globotriaosylsphingosine (Lyso-
Gb3) in lysosomes (Aerts et al., 2008; Ferraz et al., 2016a). In
symptomatic FD male plasma Lyso-Gb3 is chronically several
100-fold increased, and symptomatic female FD patients also
show increased levels of the sphingoid base (Gold et al.,
2013; Ferraz et al., 2016a). Excessive circulating Lyso-Gb3
seems a culprit, contributing to renal complications and
neuropathic pain in FD patients as the results of toxicity
for podocytes and nociceptive neurons respectively (Choi
et al., 2015; Sanchez-Niño et al., 2015). In line with this,
FD patients with Abs show a relapse of plasma Lyso-Gb3
to pre-treatment values (Ohashi et al., 2007; van Breemen
et al., 2011; Rombach et al., 2012). In view of the toxicity
of Lyso-Gb3 a treatment based on enzyme supplementation
aiming to specifically reduce this lipid might be considered.
Ideally, such therapeutic enzyme should not induce neutralizing
antibodies in FD males as occurs with Fabrazyme and
Replagal.
Plants, among others Nicotiana benthamiana
(N. benthamiana), have been shown to be excellent production
platforms of therapeutic enzymes (Fischer et al., 2004; Gomord
and Faye, 2004). Besides the amply reviewed advantages such
as associated low costs, feasibility of large scale production
and reduced risk for contaminating animal viruses and prions,
plants may be engineered to process recombinant proteins
with all post-translational modifications required for desired
bioactivity and pharmacokinetics. Shaaltiel et al. (2007) were
among the first to develop the production of a lysosomal
hydrolase in plant cells for therapeutic use in humans. They
generated recombinant glucocerebrosidase in carrot cells for
the treatment of type 1 GD. Clinical investigations with GD
patients demonstrated that the therapeutic efficacy of the plant-
produced enzyme preparation is on a par with recombinant
enzyme conventionally produced in mammalian cells. Moreover,
no significant immune responses to the plant-produced
glycoprotein as such were noted. These findings promoted swift
registration of taliglucerase (UplysoTM; Protalix) as drug for
type 1 GD in Europe, Israel, and the United States (Van Dussen
et al., 2013). Another recent example forms the production
in tobacco of acid alpha glucosidase for treatment of Pompe
disease (Su et al., 2015). Furthermore, in Nicotiana tabacum
cells a PEGylated human α-GAL enzyme has been produced for
treatment of FD (Kizhner et al., 2014). The same enzyme was
also recombinantly produced in an engineered moss cell line
by Shen et al. (2016) and shown to undergo mannose receptor
mediated uptake.
The unfortunate detrimental immune response to infused
human α-GAL’s in most FD males, leading to neutralizing
antibodies, inspired Sakubara and colleagues to propose
the use of a modified enzyme (Tajima et al., 2009). Their
alternative approach elegantly exploits the existence of a
homologous lysosomal enzyme named α-galactosidase B
or α-N-acetyl-galactosaminidase (α-NAGAL). It is encoded
by the NAGA gene (ID: 4668) (22q13.2) arisen by gene
duplication of the GLA gene. Until the late 70s both enzymes
were actually considered as different isoforms of the same
protein (Schram et al., 1977). Mature α-NAGAL, a 411
amino acid glycoprotein with 4 N-linked glycans still shows
considerably structural similarity to α-GAL. The enzyme
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α-NAGAL exerts α-N-acetyl-galactosaminidase activity,
but also hydrolyses at low rate artificial α-galactosides like
4-methylumbelliferyl-α-galactopyranoside (4MU-α-GAL)
or p-nitrophenyl-α-galactopyranoside (pNP-α-GAL). The
similarity of α-GAL and α-NAGAL is also revealed by recently
developed activity-based probes (ABPs) that bind covalently
to the catalytic nucleophile of both retaining glycosidases
(Willems et al., 2014). In the present study, we used a
similar alpha-galactosyl configured cyclophellitol-aziridine
ABP equipped with a Cy5 fluorophore, again labeling both
α-GAL and α-NAGAL. X-ray crystallography of α-GAL and
α-NAGAL provided a structural basis for the specificity
of both proteins for substrates (Tomasic et al., 2010). The
introduction of two amino acid substitutions in the catalytic
pocket of α-NAGAL, Ser188Glu and Ala191Leu, suffices
to increase about 40 times the ability of the neo-enzyme
(α-NAGALEL) to hydrolyse 4MU-α-GAL (Tajima et al., 2009).
Furthermore, it was described that α-NAGALEL reduces
Gb3 in cultured fibroblasts from a FD patient. Intravenous
administration of α-NAGALEL in FD mice partially reduced
Gb3 storage in liver, kidney, and heart (Tajima et al., 2009).
Garman recapitulated some of the findings by demonstration
of about 4.5-fold increased activity of α-NAGALEL toward
p-Nitrophenyl-α-D-galactoside, PNP-α-GAL (Tomasic et al.,
2010). The enzymes α-GAL and α-NAGAL differ not only
in affinity for the sugar-moiety of natural substrates, but also
their aglycon moieties (Clark and Garman, 2009; Guce et al.,
2010). Whereas α-GAL degrades glycosphingolipids, α-NAGAL
degrades glycopeptides and oligosaccharides as indicated by
storage materials in Schindler disease (inherited α-NAGAL
deficiency).
In our present study, we investigated whether it is feasible
to produce in N. benthamiana leaves α-GAL, α-NAGAL, and
α-NAGALEL. All plant-produced enzymes were active and
could be labeled by the Cy5 equipped ABP. The glycosidases
were purified to homogeneity and characterized regarding
enzymatic activity toward artificial alpha-galactoside and
alpha-N-acetylkgalactosiminide substrates, and their N-glycan
composition. In addition, we produced the same enzymes in
HEK293 cells, showing no difference in specific activities to
the ones produced in the N. benthamiana leaves. Moreover, we
established whether the enzymes cross react with antibodies
in serum of an FD patient with neutralizing activity (Linthorst
et al., 2004). Next, we studied the activity of the various
enzymes toward lipid substrates, in particular Gb3 and Lyso-
Gb3. Finally, we examined the stability of various enzymes
in plasma and their ability to degrade excessive Lyso-Gb3
in FD sera using LC–MS/MS and isotope-encoded internal
standards (Gold et al., 2013; Ferraz et al., 2016a). From
the results obtained we conclude that it seems feasible to
produce a modified α-NAGALEL that is more stable in human
plasma than α-GAL and is better able to degrade excessive
Lyso-Gb3 in FD serum. Further tailoring of an enzyme to
optimally degrade circulating Lyso-Gb3 in the blood of FD
patients is a therapeutic avenue to be considered, and plants




Nicotiana benthamiana plants were grown at 21◦C and 60–70%
humidity in the Unifarm greenhouses of Wageningen University
(Westerhof et al., 2014).
Chemicals
All chemicals were obtained from Sigma (Germany) if not
indicated otherwise. Fluorescent NBD-lipids and pure lipids were
purchased from Avanti (Alabama, United States). Antibodies
purchased from Abcam (Cambridge, MA, United States).
Activity Based Probe (ABP)
The fluorescent ABP directed against α-galactosidases was
produced based on previously described synthesis (Willems
et al., 2014). Alpha-Galactopyranose configured cyclophellitol-
aziridine was grafted with Cy5 as fluorophore, as described in
detail in the Supplementary Material (Scheme 1). The newly
synthesized probe was examined on reactivity with human
recombinant α-GAL (Fabrazyme, Sanofi-Genzyme, Cambridge,
MA, United States) (Supplementary Figures S1A,B).
Preparation of Human α-GAL, α-NAGAL,
and α-NAGALEL (S188E; A191L) Plant
Expression Vectors
Both GLA (ID: 2717) and NAGA (ID: 4668) were amplified
from MegaMan Human Transcriptome cDNA library
(Stratagene). The coding region of genes was amplified by
Phusion R© HighFidelity PCR MasterMix (BioLabs) using the
following primers: GLA sense: 5′-CTCATGAGTGCCAAGACC
AACCTCTTCCTCTTCCTCATCTTCTCCCTCCTGCTCTCC
CTC TCCTCCGCCCTGGACAATGGATTGGCAAG-3′, GLA
antisense: 5′-CCCGTACGTTAAAG TAAGTCT-3′, NAGA
sense: 5′-CTCATGAGTGCCAAGACCAACCTCTTCCTCTT
CCTCATC TTCTCCCTCCTGCTCTCCCTCTCCTCCGCC-3′,
NAGA antisense: 5′-CCGTACGTCACTGCT GGGACA-3′.
The genes were amplified between BspHI and BsiWI restriction
sites, lacking the sequence encoding for their native signal
peptide. Instead, the native signal peptide of Arabidopsis
thaliana chitinase was added at primer sequences. Insertion of
mutations S188E and A191L in NAGA gene was achieved via
overlap extension PCR. PCR reactions were performed using
the following primers: NAGA mutant antisense: 5′-CCTTCA
TAGAGTGGCCACTCGCAGGAG AAGGC-3′, NAGA mutant
sense: 5′-GCCTTCTCCTGCGAGTGGCCACTCTATGAAGG-
3′. The elements were cloned into pGEM -T Easy Vector System
(Promega), following electroporation of DH5α Escherichia coli
cells. After clone selection and confirmation of sequences by
sequencing (Macrogen), the complete open reading frames
(ORFs) of GLA, NAGA, and NAGAEL were inserted in plant
expression vectors. A modified version of pMDC32 expression
vector, named pHYG (Westerhof et al., 2012), was used as
the main plant expression vector during all experiments. The
vector was digested with Acc65I and NcoI, leaving compatible
overhangs for ligation of the elements flanked between BspHI
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and BsiWI restriction sites. All constructs were under the control
of cauliflower mosaic virus 35S constitutive promoter, with
duplicate enhancer (d35S) and the nopaline synthase terminator
(Tnos) derived from Agrobacterium tumefaciens. The pHYG
vectors harboring the genes were used for transformation
of Agrobacterium tumefaciens strain MOG101, following
N. benthamiana plant leaf infiltrations.
Agrobacterium tumefaciens Transient
Transformation Assay
Agrobacterium tumefaciens cultures were grown as previously
described (Westerhof et al., 2012, 2014). The constructs were
co-expressed or not with the tomato bushy stunt virus silencing
inhibitor p19 (Voinnet et al., 2003), by mixing the bacterial
cultures 1:1 following 1–2 h incubation at room temperature.
Infiltration of Plants, Harvesting, and
Lysate Preparation
The inoculated bacterial cultures were used for infiltration of the
two youngest leaves of 5–6 weeks old N. benthamiana plants,
to ensure optimum protein expression, as previously described
(Westerhof et al., 2014). Whole leaves and leaf disks (50 mm)
were harvested at different days post-infiltration (dpi), snap-
frozen and homogenized in liquid nitrogen. Homogenization was
performed with a tissue lyser (AKA Qiagen TissueLyser II) at
30 rounds/sec for 1 min. Extraction of total soluble proteins of
samples was achieved using 2–3 ml per leaf gram of extraction
buffer (30 mM citrate-phosphate buffer, pH 6.3, containing 2%
(w/v) polyvinylpolypyrrolidone, 0.1% (v/v) Tween 20, 0.5 M
NaCl, and protease inhibitor by Roche, EDTA free) following
homogenization at same tissue lyser program. When whole leaves
were used, homogenization was performed by grinding with a
mortar and pestle. Samples were next centrifuged for 15 min at
15000 g (F13S 14× 50 cy, Sorvall rotor), at 4◦C. The supernatant
was collected and used for further analysis or it was stored at
−80◦C after desalting at G25-Sephadex column.
Enzyme Purification
As first step in the purification of all enzymes, a 5 ml column
of Concanavalin-A-Sepharose (GE healthcare Bio-Sciences) was
used. The column was equilibrated with 40 ml washing buffer
(0.1 M sodium acetate, 0.1 M NaCl, 1 mM MgCl2, 1 mM
CaCl2, 1 mM MnCl2, pH 6.0). Then, protein sample (lysate)
was applied to the column, 1:1 diluted in washing buffer
(0.5 ml/min loading conditions). For α-GAL 49 ml of protein
lysate was applied on the column, for α-NAGAL 38 ml and
α-NAGALEL 25 ml. Proteins were eluted with 30 ml elution buffer
(washing buffer supplemented with 0.9 M methyl-α-mannoside
and 0.9 M methyl-α-glucoside). Ten fractions of 1 ml showing
highest levels of enzymatic activity were pooled (post-ConA).
Next, for α-GAL purification, 10 ml of post-ConA was loaded
on an ultrafiltration device (Centricon Plus-20, 15 ml with
10 kDa molecular cutoff, Millipore, Bedford, MA, United States)
to remove methyl-monosaccharides and buffer exchanged to
20 mM sodium acetate, pH 5.0, until obtaining a volume of
3 ml. Dialysis of the sample was continued in 20 mM sodium
acetate buffer, pH 5.0, 4◦C, overnight. A HiTrap SP HP column
(1 ml; GE healthcare Bio-Sciences) was equilibrated with 15 ml
binding buffer: 20 mM sodium acetate buffer, pH 5.0. The
sample, 3 ml, was applied on the column which was extensively
washed with 10 ml binding buffer afterward. Then, protein was
eluted using a gradient of 0–300 mM NaCl, 15 ml. Enzyme
eluted in 0.5 ml fractions 2–4, which were pooled. For wild
type α-NAGAL and modified α-NAGALEL, post-ConA, 2–3 ml,
was buffer exchanged via ultrafiltration to 10 mM potassium
phosphate buffer, KPi (pH 6.3) with 10 mM NaCl. Next,
sample was dialyzed in the same buffer to further remove any
methyl-monosaccharides. After this, sample was applied on a
HiTrap Q HP column (1 ml; GE healthcare Bio-Sciences). Anion
exchange chromatography was performed using a gradient of
10–600 mM NaCl in 10 mM KPi (pH 6.3). Enzymes eluted in
0.5 ml fractions 2–4, which were pooled. As final purification
step for all enzymes gel filtration was used. A SuperdexTM
200 Increase 10/300 GL (GE healthcare Bio-Sciences) column
was prior equilibrated with 50 ml of 20 mM sodium acetate
buffer with 150 mM NaCl, pH 5.0. Samples were applied
and chromatography performed at a flow 0.75 ml/min. 0.2 ml
fractions were collected and analyzed on enzymatic activity. The
final material was snap frozen in liquid nitrogen and stored at
−80◦C until further use.
Overproduction of α-GAL, α-NAGAL, and
α-NAGALEL in HEK293 Cells
Vectors for human cell line HEK293 were produced as
follows: the complete OPFs of human α-GAL, α-NAGAL,
and α-NAGALEL were amplified from previous pGEMt easy
vectors harboring the genes with their native signal peptide, via
PFX50 high fidelity DNA polymerase (Invitrogen), using the
primers below. GLA sense: 5′-GGGGACAAGTTTGTACAAAA
AAGCAGGCTACCACCATGCA GCTGAGGAA CCCAGA-3′,
GLA antisense: 5′-GGGGACCACTTTGTACAAGAAAGCTG
GGTC TTAAAGTAAGTCTTTTAATGACATC-3′, NAGA sense:
5′-GGGGACAAGT TTGTACA AAAA AGCAGGCTACCA
CCATGCTGCTGAAGACAGTGCTC-3′, NAGA antisense:
5′-GGGGACCA CTTTGTACAAGAAAGCTGGGTCTCAGCT
GGGACATCTCCAG-3′. The elements were cloned via Gateway
cloning into the donor vector pDONR221 (BP reaction),
following transformation of DH5α E. coli strain. Clones were
collected upon ampicillin selection and their sequences were
confirmed. Next, they were cloned into the destination vector,
pcdna-DEST40-zeo (LP reaction), forming the final construct
to transfect HEK293 cells. The HEK293 cells were cultured in
six well plates in 2.5 ml Dulbecco’s Modified Eagles Medium
(DMEM, Sigma) supplemented with 10% fetal calf serum, 1%
penicillin/streptomycin and glutamax at 37◦C, at 7% CO2.
Three µg of pcdna-DEST40-zeo DNA was transfected into
cultured HEK293 cells using polyethylenimine, primarily mixed
with serum free DMEM medium. After 2 days of cell culture,
200 µg/µl of zeocin was added to the culture media for selection
of clones harboring the gene of interest. The cells grew for
3 weeks at 37◦C, at 7% CO2 in the presence of antibiotics and
lysed in 20 mM KPi buffer (pH 6.5), 0.1% Triton with additional
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protease inhibitor by Roche. The cells were stored at −150◦C in
DMEM, 20% fetal calf serum, 10% DMSO until further use.
Enzymatic Activity Measurements
Both α-galactosidase A and α-N-acetyl-galactosaminidase
activities of samples were examined with corresponding 4-
methylumbelliferyl (4MU) substrates. For α-galactosidase
activity measurement samples were incubated for 1 h
at 37◦C with a final concentration of 1.2 mg/ml 4MU-
α-D-galactosylpyranoside (4MU-α-GAL) in 150 mM
citrate-phosphate buffer pH 4.6, supplemented with 0.1%
(w/v) BSA and released 4MU was quantified as described earlier
(Blom et al., 2003).
Activity of plant produced recombinant enzymes and
Fabrazyme toward 5 µM of NBD-C12-Gb3 substrate was
measured for 3 h at 37◦C in 150 mM citrate-phosphate buffer
(pH 4.6) containing 0.05% (v/v) Triton X-100 and 0.2% (w/v)
sodium taurocholate, pH 4.6. Lipids were extracted with the
Bligh and Dyer procedure, applied to HPTLC. The plate was
scanned for fluorescent lipids with a Typhoon FLA 9500. Protein
concentrations in assay were for Fabrazyme 3.8 µg/ml, α-GAL
3.2 µg/ml, α-NAGAL 40 µg/ml, and α-NAGALEL 16 µg/ml.
Activity of recombinant enzymes toward natural C18: Gb3 was
measured using 500 pmol of lipid in (100 µl total volume)
150 mM citrate-phosphate buffer with 0.05% (v/v) Triton X-100
and 0.2% (w/v) sodium taurocholate for 3 h at 37◦C. The pH
was 4.2 for α-GALs and 5.2 for α-NAGALs. After incubation,
neutral lipids were extracted by the Folch method. Deacetylation
of lipids was performed as described earlier (Ferraz et al., 2016b).
After deacetylation, samples were dried and further cleaned by
adding 1:1 butanol: water. The butanol phase was collected,
dried and lipids were dissolved in 200 µl methanol, ready for
LC–MS/MS injection. The conversion of Gb3 to lactosylceramide
(Lac Cer) was measured in LC–MS/MS using C17-Gb3 and C17-
Lac Cer as controls and C17-Sphinganine as internal standard.
The same assay conditions were used when applying natural
Lyso-Gb3 as substrate. Lipids were extracted according to Bligh
and Dyer and subjected to LC–MS/MS injection as above.
Isotope 13C-Lyso-Gb3 was used as an internal standard for
monitoring the conversion of Lyso-Gb3 into Lyso-Lac Cer.
Protein concentrations in assays were for Fabrazyme 1.9 µg/ml,
α-GAL 1.6 µg/ml, α-NAGAL 20 µg/ml, and α-NAGALEL
8 µg/ml.
Determination of Kinetic Parameters
Km, Vmax, and kcat values were determined using 4MU substrates.
Reactions were performed for 1 h or 30 min at 37◦C at 10
different 4MU-α-GAL and 4MU-α-NAGAL concentrations in
150 mM citrate-phosphate buffer pH 4.6 supplemented with
0.1% (w/v) BSA. The 4MU-α-GAL concentrations in the assays
ranged from 0.074 to 4.72 mM; for 4MU-α-NAGAL from
0.022 to 0.91 mM. Protein concentrations in the assays were:
for α-GAL 7 ng/ml, Fabrazyme 2 ng/ml, α-NAGAL 16 ng/ml,
when using 4MU-α-NAGAL substrate and 100 ng/ml, when
using 4MU-α-GAL substrate, and for α-NAGALEL 16 ng/ml.
Parameters were calculated using GraphPad Prism6.
N-glycan Analysis of Plant Produced
α-Galactosidases
Proteins were deglycosylated with EndoH and PNGase F (Wilbers
et al., 2016). MALDI-TOF analysis performed as previously
described (Wilbers et al., 2016).
Sodium Dodecyl Sulfate-Polyacrylamide
Gel Electrophoresis
To examine purity and molecular mass of recombinant
α-galactosidases, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS- PAGE) (10% polyacrylamide) was used
(Witte et al., 2010). Samples were run under reduced conditions.
After SDS-PAGE analysis, gels were stained with Coomassie
Brilliant Blue staining or silver stain using the PhastSystem
system (GE Healthcare).
ABP-Based Fluorescence Staining
The α-GAL Cy5 ABP was diluted in 150 mM citrate-phosphate
buffer, pH 5 and applied to lysates or pure protein preparations
at 0.5 or 0.25 µM final concentration, respectively. The samples
were incubated for 30 min, at 37◦C and the reaction was
stopped via the addition of 4x gel loading buffer (containing
β-mercaptoethanol). The samples were then boiled for 5 min at
95◦C and loaded on 10% SDS-PAGE gels. Subsequently, western
blotting and fluorescence scanning was performed exactly as
described earlier (Witte et al., 2010; Willems et al., 2014).
Protein Determination
Protein concentrations were determined with a Micro BCA
Protein Assay Reagent Kit (PIERCE), and bovine serum albumin
was used as a standard, according to the supplier’s protocol. In
addition, pure protein concentrations were measured in Nano
Drop 2000c (Thermo Scientific) via adjusting the molecular
weight and extinction coefficient parameters.
Detection of Cross Reactivity with
Antibody (Ab)-Positive FD Serum
Samples were incubated for 1 h 4◦C while rolling, with 2 µl Ab+
FD serum or normal serum of an FD patient and α-galactosidase
activity was measured with 4MU-α-GAL and 4MU-α-NAGAL
substrate (Linthorst et al., 2004).
Degradation of Lyso-Gb3 in FD Serum
To serum from two different FD patients pre-ERT, recombinant
enzymes (8 µmol artificial substrate hydrolysis/h/ml) were added
and incubated overnight at 37◦C. Then, lipids were extracted as
described before and applied to LC–MS/MS.
RESULTS
Transient Production of Human
α-Galactosidases in N. benthamiana
Leaves
We first established the optimal conditions for production
of α-galactosidases α-GAL, α-NAGAL, and α-NAGALEL in a
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FIGURE 1 | Production of α-galactosidases α-GAL, α-NAGAL and
α-NAGALEL in transiently transformed Nicotiana benthamiana leaves.
Samples were harvested 1, 3, and 5 days post-infiltration (dpi) either or not
co-expressed with P19 silencing inhibitor. (A) Enzymatic activity was
measured with corresponding 4MU-substrate (Represented in black the 4MU
activity of lysates harvested in 1st Dpi, light gray 3rd Dpi, dark gray 5th Dpi)
(n = 4, error bars indicate mean ± standard deviation). Asterisk(s) indicate
significant differences as measured by a two-way ANOVA corrected using
Bonferroni post hoc tests, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). (B) ABP
detection of active enzyme molecules present in plant lysates. As controls an
empty vector sample (E.V) and an untreated plant leaf (P.L). The gels were
stained with Coomassie Brilliant Blue staining (CBB) as a loading control.
(C) Western blot analysis of the plant produced α-galactosidases using
anti-α-GAL and anti-NAGA polyclonal rabbit antibodies raised against the
human homolog. As control an empty vector sample (E). Black asterisk
indicating the α-NAGALs and red asterisk the α-GAL.
transient expression system in N. benthamiana. In the constructs
the sequences of mature α-galactosidases were preceded by that of
the Arabidopsis thaliana chitinase signal peptide. Agrobacterium
tumefaciens infiltrated leaves of 5–6 weeks old N. benthamiana
plants were collected at 1, 3, and 5 days post-infiltration (dpi),
lysates were prepared and enzymatic activities of α-galactosidases
were measured using the respective 4MU substrate (Figure 1A).
For each enzyme, an optimal yield was observed at 5 dpi,
while co-expressing the p19 silencing suppressor of tomato
bushy stunt virus. This time point was used throughout all later
experiments for harvesting. The amounts of active recombinant
α-GAL, α-NAGAL and α-NAGALEL at 5 dpi was 71, 5 and
7 nmol/h/µg total protein, respectively, as measured with 4MU-
α-GAL substrate. No 4MU-α-NAGAL activity was detected
for the α-NAGALEL enzyme, whereas the wild type reached
33 nmol/h/µg at 5 dpi (Figure 1A). The amount of enzyme
activity was proportional to the amount of active enzyme
molecules detected with the fluorescent ABP (Figure 1B) and
that detected with western blotting using anti-α-GAL and
α-NAGAL antibodies (Figure 1C). The molecular weight of
α-GAL was about 44 kDa. Those of the two α-NAGALs
were about 49 kDa, the higher mass being due to the
known presence of one extra N-glycan (Clark and Garman,
2009).
Purification and Biochemical
Characterization of Plant Produced
α-Galactosidases
Recombinant α-galactosidases were purified from lysates of
N. benthamiana leaves by sequential chromatography during
which the presence of enzymes was monitored by measurement
of enzymatic activities with 4MU-substrates. As generic first
step we used Concanavalin A-Sepharose chromatography
exploiting the presence of mannose-containing N-glycans
in the recombinant α-galactosidases ensuring high affinity
binding to the immobilized lectin (Yasuda et al., 2004). The
recovery in this step was high (>40%) for each enzyme
and led to >50-fold purification (Table 1). The next step in
purification was ion exchange chromatography performed
at pH 5.0 for α-GAL and at pH 6.3 for α-NAGAL and
α-NAGALEL as described in experimental procedures. This
led for each enzyme to considerable further purification with
acceptable recovery (Table 1). The final purification step
for all enzymes was gel filtration, resulting in an apparently
pure protein as judged by silver staining of protein resolved
by SDS-PAGE (Figure 2A). About 1 µg α-GAL, α-NAGAL,
and α-NAGALEL was purified from 1 mg of soluble lysate
protein.
The apparent molecular weights of all three α-galactosidases as
determined by gel filtration coincided with dimers (113 kDa for
α-GAL, 134 kDa for α-NAGAL, and 132 kDa for α-NAGALEL)
(Supplementary Figures S2A,B). Of note, the specific activity of
plant-produced α-GAL (2.35 mmol/h/mg) was quite comparable
to that of Fabrazyme (2.18 mmol/h/mg) (Table 2) (Tajima
et al., 2009). After purification, further enzyme characterization
was performed. Equal µg amounts of pure enzymes were
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TABLE 1 | Overview of enzyme purifications.








% Yield = recovery
of activity
α-GAL Plant extract 49 136 3412 25 0 100
Con-A 3 1.3 1928 1444 57 57
Cation exchange 2 0.4 860 2151 86 25
Gel filtration 1.4 0.12 308 2585 103 9
α-NAGAL Plant extract 38 135 319 2.3 0 100
Con-A 3 1 112 107 45 35
Anion exchange 4 0.7 94 132 56 30
Gel filtration 2 0.14 29.5 211 89 9
α-NAGALEL Plant extract 25 64 314 5 0 100
Con-A 2 0.45 122 270 55 49
Anion exchange 4 0.2 55 273 56 17
Gel filtration 1.2 0.056 28 501 102 9
incubated with fluorescent ABP followed by SDS-PAGE and
fluorescence scanning analysis (Figure 2B). The intensity
of the fluorescently labeled bands was the same for the
three enzymes, revealing similar amounts of active enzyme
molecules in each purified protein preparation. Western blotting
using anti-α-GAL and anti-α-NAGAL antibodies showed that
α-NAGALEL was not recognized by anti-α-GAL antibody
(Figure 2B).
N-glycan Profile of the Plant Produced
Enzymes
Next, the N-glycan composition of the purified α-galactosidases
was examined using deglycosylation with Endo H and PNGase
F endoglycosidases following SDS-PAGE analysis. Fabrazyme,
produced in CHO cells, was used as a control. Consistent with
literature reports, PNGase F led to conversion of Fabrazyme
to a molecular mass of 39 kDa (Figure 3A). In the case
of plant produced enzymes the reductions in molecular mass
with EndoH or PNGase F were less pronounced (Figure 3A).
This difference can be attributed to the presence of α1-
3 core fucose residues, attached to most of the N-acetyl-
glucosamine backbones (GlcNAc), inhibiting digestion by the
endoglycosidases. The higher molecular weight of Fabrazyme
compared to the plant produced enzymes could be due to
the different N-glycan composition of this enzyme, mainly
consisting of complex N-glycan structures, with additional
mannose 6 phosphate residues (Sakuraba et al., 2005). To get
more insight in the N-glycan composition of the plant produced
enzymes, all N-linked glycans were released with PNGase A
(not inhibited by the presence of α1-3 fucose) and subjected
to MALDI-TOF MS (Figures 3B–D). The most prominent N-
glycan type of α-GAL recombinant protein was paucimannose
structure (Man3GlcNAc2) with α1-3 fucose attached on the core
GlcNAc and β1-2 xylose on the first mannose. Conceivably, the
enzyme was secreted to the apoplastic fluid and hexosaminidases
cleave the GlcNAc molecules yielding the pausimanosidic
structure. On the other hand, both α-NAGALs have oligo-
mannose type N-glycans (Man7GlcNAc2) as the most abundant
N-glycan type, suggesting their retention in Golgi and /or ER
compartments.
Cross Reactivity with Antibodies (Ab) in
Fabry Serum and Stability Tests
We next examined the cross reactivity of recombinant
α-galactosidases toward neutralizing antibodies in the serum of
an Ab-positive male FD patient receiving ERT for 6 years (T= 1).
As a control, serum was used of the same patient before ERT
(T = 0) and still lacking antibodies against therapeutic α-GAL.
Inhibition of enzymatic activity by presence of Ab-positive
serum was determined (Figure 4A). Activity of plant produced
α-GAL and Fabrazyme was clearly inhibited, but activities of
α-NAGALs, as determined with 4MU-α-GAL and/or 4MU-
α-NAGAL substrates were not significantly influenced. The
stability of the plant-produced galactosidases and Fabrazyme in
human plasma was next studied by incubating enzymes at 37◦C
for different time periods and detection of residual enzymatic
4MU-α-GAL activity (Figure 4B). Alpha-NAGALEL, like
α-NAGAL, was more stable than both α-GALs (Figure 4B). The
finding was made several times with independent incubations.
Enzymatic Activities of Plant Produced
α-GAL, α-NAGAL, and α-NAGALEL
toward Artificial Substrate(s) and Their
Comparison with the Same Enzymes
Produced in HEK293 Cells
We next studied the substrate specificity of the various
recombinant α-galactosidases. First, activity was measured
toward artificial 4MU-α-GAL and 4MU-α-NAGAL substrates.
The amino acid substitutions Ser188Glu and Ala191Leu in
the catalytic pocket of α-NAGAL (α-NAGALEL) abolished
activity toward 4MU-α-NAGAL as earlier reported (Tajima
et al., 2009; Tomasic et al., 2010) (Table 2). The noted
increase in hydrolytic specific activity toward 4MU-α-GAL
(about a doubling) was less prominent as earlier reported by
Tajima et al. (2009). The kinetic parameters kcat and Km
Frontiers in Plant Science | www.frontiersin.org 7 June 2017 | Volume 8 | Article 1026
fpls-08-01026 June 19, 2017 Time: 13:1 # 8
Kytidou et al. In planta Produced Human α-Galactosidases
FIGURE 2 | Overview of enzyme purifications: activity based probe detection,
Immunoblotting and Coomassie Brilliant Blue, staining of the plant produced
pure enzymes. (A) SDS-PAGE and silver staining of fractions obtained during
purification. Four µg of total protein per lane was loaded for all unpurified
samples and 1–2 µg for all pure protein fractions (α-NAGAL, α-NAGALEL, and
α-GAL). Shown are: starting material/Lysate (L), bound protein to
Concanavalin A (C), pooled collected eluate of ion exchange (I), and the final
pooled gel filtration fraction (GL) with highest enzyme specific activity. For
comparison is shown recombinant α-galactosidase A, Fabrazyme (Fz). Black
asterisk indicating the α-NAGALs and red asterisk the α-GAL. (B) Before
electrophoresis, 1 µg of each pure enzyme was treated with 0.25 µM of Cy5
α-galactosidase activity based probe, ABP. NEL = α-NAGALEL, N = α-NAGAL,
A = α-GAL. The gels were scanned λexc = 635 nm, then immunoblotted with
anti-α-GAL or anti-NAGAL rabbit polyclonal antibodies, following Coomassie
Brilliant blue, CBB, staining of the blots. The same gel had to be repeated
since anti-α-GAL and anti-NAGA antibodies were both polyclonal anti-rabbit.
determined with 4MU-α-GAL as substrate were improved by
the amino acid substitutions in α-NAGALEL (Table 3). The
plant produced α-GAL showed comparable kinetic parameters
to Fabrazyme (Table 3) (Hopkin et al., 2003; Lee et al., 2003).
To determine whether production in N. benthamiana leaves
influences kinetic features, the various recombinant enzymes
were also generated in human HEK293 cells as described in
experimental procedures (Figure 5A). ABP-labeling showed that
similar proteins were produced in N. benthamiana and HEK293
cells (Figure 5B). The specific activity toward 4MU-α-GAL
was also comparable, being relatively low for α-NAGAL and
increased (threefold) by the amino substitutions in α-NAGALEL
(Figure 5C).











Activity of Recombinant Enzymes toward
(Semi) Natural Substrates
The activity of plant produced galactosidases toward lipid
substrates was next determined. NBD-Gb3 was found to be
degraded by Fabrazyme and plant-produced α-GAL on a par
(Figure 6A). Of note, significant degradation of NBD-Gb3 to
NBD-Lac Cer by α-NAGAL and α-NAGALEL was detected
(Figure 6A). To further substantiate the findings, we incubated
wild type and mutant α-NAGALs with NBD-Gb3 in the absence
or presence of 2.5 mM N-acetylgalactosamine, a potent inhibitor
of α-NAGAL activity (Figure 6B). The wild type α-NAGAL
was inhibited, resulting in loss of NBD-Lac Cer formation,
whereas α-NAGALEL was not. Next, activity toward 5 µM of
natural Gb3 and its deacetylated form Lyso-Gb3, was determined
using detection of metabolites with LC–MS/MS. The analysis
revealed a 2–5-fold increased activity of α-NAGALEL compared
to α-NAGAL with both substrates (Figure 6C). The pH optimum
was pH 4.2 for α-GALs and pH 5.2 for both α-NAGALs
(Supplementary Figure S3).
Finally, serum of male FD patients, containing high amount
of Lyso-Gb3, was incubated overnight with recombinant
galactosidases (at a concentration of 8 µmol/h/ml activity
mimicking levels reached during ERT). Of note, the rate of
degradation of Lyso-Gb3 in the serum sample was highest with
α-NAGALEL (Figure 6D). Likely this reflects the greater stability
and ongoing activity of α-NAGALEL at neutral pH as compared
to that of α-GALs.
DISCUSSION
The combined challenges of high costs, immunogenicity and
poor efficacy posed by present Fabry ERT’s prompted us to
consider an examination of wild type and mutant recombinant
human α-galactosidases. N. benthamiana leaves, as production
system, allowed expression of all enzymes at substantial amounts,
0.1–0.2% of total soluble protein. We used agro-infiltration of
N. benthamiana leaves for the production of the enzymes as a
reliable, low cost and fast method for transient gene expression.
N. benthamiana is a rapidly growing plant species, which
leaves can be easily infiltrated with Agrobacterium tumefaciens
harboring the genes encoding the enzymes to be produced.
In addition, a high variety of expression vectors available for
Nicotiana plants provide another advantage of using this species
for recombinant protein production (Chen et al., 2013; Leuzinger
et al., 2013). Further, the composition of N-glycans can be
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FIGURE 3 | N-glycans of α-galactosidases. (A) SDS-PAGE analysis followed
by Coomassie Brilliant Blue staining of 1 µg pure plant produced proteins and
3 µg of Fabrazyme. E = protein treated with Endo H, F = protein treated with
PNGase F, C = untreated protein. (B–D) N-glycosylation profiles were
determined by MALDI-TOF MS analysis of 2-aminobenzoic acid derivatised
PNGase-A released N-glycans of plant produced galactosidases. Glycan
structures depicted were deduced from the measured m/z values. Blue
square, N-acetylglucosamine; red triangle, fucose; open star, xylose; green
circle, mannose. Presented N-glycan profiles of the following proteins: (B)
α-GAL, (C) α-NAGAL, (D) α-NAGALEL.
FIGURE 4 | Inhibition of activity of α-galactosidases by Ab-positive Fabry
serum. (A) Percentage inhibition by FD serum, obtained after 6 years ERT
(T = 1), of enzymatic activity measured with 4MU-α-GAL and 4MU-α-NAGAL.
As negative control, serum of FD patient pre-ERT (T = 0), was used.
Asterisk(s) indicate significant difference as measured by a two-way ANOVA,
∗∗∗∗P < 0.0001. (B) Percentage activity after incubation of 1 µg/ml pure
enzyme in human plasma for 15, 30, 45, and 60 min.
tailored in N. benthamiana variants (Wilbers et al., 2016).
Stable expression of the glycosidases might be considered to
eliminate inter-batch yield variations. A priori the production
in another “plant” host might also be considered, for example
stable expression in lettuce (Lactuca sativa), algae or moss,
in order to conceivably enhance yields and to avoid the high
levels of phenolic and toxic alkaloids present in Nicotiana plants
that might affect the purification procedures (Hempel et al.,
2011; Chen et al., 2013; Xu and Zhang, 2014; Reski et al.,
2015). Furthermore, recombinant human α-GAL has earlier been
successfully produced in cultured Nicotiana tabacum cells and
in an engineered moss cell line, eliminating possible transgene
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α-GAL 2.478 4.219 55.96 22.58 No activity detected
α-NAGAL 6.02 0.527 6.89 1.14 0.7 3.9 25.51 36.13
α-NAGALEL 3.18 0.71 14.52 4.79 No activity detected
Fabrazyme 2.431 3.954 52.11 21.43 No activity detected
flow that might occur while using whole plants as production
platforms (Kizhner et al., 2014; Shen et al., 2016).
The presently expressed α-GAL seems most likely to be
secreted or transported to the vacuole as based on its
N-glycan composition consisting largely of Man3GlcNAc2 with
α1-3 fucose attached to the core GlcNAc and β1-2 xylose
to the first mannose (Castilho and Steinkellner, 2012). In
contrast, the transiently expressed α-NAGALs show prominent
Man7GlcNAc2 N-glycans, more consistent with retention in the
cis Golgi or ER (Castilho and Steinkellner, 2012). Some bias
might be introduced by the lectin purification step. However, the
recovery of enzymes in the lectin binding step is high, minimizing
the bias. The observed specific activities of the purified
enzymes were in the range of single digit nanomole substrate
hydrolysis/µg pure protein per hour, being comparable to that of
Fabrazyme. Recombinant, plant produced galactosidases were all
labeled by fluorescent α-galactosyl cyclophellitol-aziridine ABP.
The intensity of ABP labeling per protein amount was identical
for all galactosidases, substantiating further that in all cases the
majority of purified protein is enzymatically active.
The observed specific activities of the produced
α-galactosidases warrant discussion. The specific activity of
pure α-NAGALEL (0.55 mmol/h/mg) as measured with 4MU-
α-GAL was 2–3-fold increased to that of wild type α-NAGAL
(0.19 mmol/h/mg). The Km of α-NAGALEL (3 mM) was lower
compared to that of α-NAGAL (6 mM). Almost the same
specific activity for α-NAGALEL (0.5 mmol hydrolysis/h/mg)
was reported by Sakuraba and co-workers (Tajima et al., 2009).
They related this to that of wild type α-NAGAL from a different
source, resulting in an apparent 43-fold improved α-galactosidase
activity imposed by the introduction of the S188E and A191L
in α-NAGAL (Tajima et al., 2009). Our results are in closer
alignment with those of Garman and co-workers (Tomasic et al.,
2010). Using p-nitrophenyl-α-Gal as substrate the kcat/Km value
of α-NAGALEL was found to be 4.6-fold higher than that of
α-NAGAL, similar to the fourfold increase of kcat/Km value with
4MU-α-GAL substrate observed by us (Tomasic et al., 2010).
Comparison of plant produced α-GAL with Fabrazyme revealed
that their specific activities toward 4MU-α-GAL, as well as Gb3,
are almost identical. We also produced the various recombinant
α-galactosidases in mammalian HEK293 cells showing similar
kinetic parameters as the plant-produced enzymes, indicating
that these are not influenced by the production platforms.
Fabrazyme produced in CHO cell line contains the sialic
acid N-glycolylneuraminic which does not occur in humans
and therefore is potentially immunogenic (Bekri, 2006; Castilho
and Steinkellner, 2012; Kizhner et al., 2014, 2016). The plant-
produced recombinant enzymes of the current study do not
contain N-glycolylneuraminic acid in their N-glycans. The
N-glycan profiles of all plant-produced recombinant enzymes
were relatively homogenous, but differences were seen in
N-glycans among the various enzymes. Most importantly,
the majority of N-glycans of all recombinant enzymes were
found to be core α1-3 fucosylated and β1-2 xylosylated. The
same modifications occur in N-glycans of carrot-produced
taliglucerase (human glucocerebrosidase) (Shaaltiel et al., 2007).
Of note, there is no evidence that these modifications induce
immune responses in GD patients (Shaaltiel et al., 2007). A priori
this does not exclude immunogenicity in FD patients.
The recombinant enzymes produced in N. benthamiana lack
M6P residues. In theory, the glycans may be swapped for other
structures through the chemoenzymatic methodology developed
by Fairbanks and colleagues (Priyanka et al., 2016). However,
given the limited success of existing Fabry ERT aiming at M6P
receptor mediated delivery of therapeutic enzyme to lysosomes
it might be considered to refrain from this type of enzyme
targeting. We earlier demonstrated that deacylated Gb3, Lyso-
Gb3, is extremely elevated in FD patients and α-galactosidase
A deficient mice (Aerts et al., 2008; Ferraz et al., 2016b).
Excessive Lyso-Gb3 has been shown to be toxic for nociceptive
peripheral neurons and podocytes in FD patients (Choi et al.,
2015; Sanchez-Niño et al., 2015). Reduction of Lyso-Gb3 in
FD patients therefore seems a valid therapeutic goal. In view
of this consideration above, our finding that not only α-GAL
but also α-NAGALs are able to degrade Gb3 and Lyso-Gb3
is of interest. The amino acid substitutions in α-NAGALEL
improve∼2-fold the capacity of the enzyme to degrade Lyso-Gb3
and ∼5-fold that for Gb3. The relative efficacy of α-NAGALEL
compared to α-GAL in ability to degrade Lyso-Gb3 in FD
serum is even better. The greatest reduction of Lyso-Gb3 is
detected with α-NAGALEL added to FD serum at 37◦C. The
superior action of α-NAGALEL is likely due to its stability at
neutral pH. This remarkable finding suggests that the use of
non-antigenic (modified) α-NAGAL might be a way to reach
desired reductions in circulating Lyso-Gb3. The use of (modified)
α-NAGALs benefits from the higher stability and activity of
the enzyme at neutral pH as compared to α-GAL. PEGylation
could be employed to increase the presence of (modified)
α-NAGAL in the blood. Of note, endogenous α-NAGAL in the
circulation of normal individuals and FD patients is relatively low
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FIGURE 5 | Comparison of the biochemical properties of recombinant
galactosidases produced in plants and HEK293 cells. (A) Overexpression of
human galactosidases in HEK293 cells was estimated via SDS-PAGE
analysis. 20 µg of total soluble protein were incubated with 0.5 µM of Cy5
ABP, following Western blot analysis and Coomassie Brilliant Blue, CBB,
staining of the blot. (B) ABP labeling of active enzyme molecules present in
HEK293 and plant lysates overexpressing the proteins α-NAGALEL,
α-NAGAL, and α-GAL. Different total protein content was loaded in each lane.
(C) The 4MU-α-GAL specific activities of HEK293 and plant lysates
overexpressing the human galactosidases.
(Aerts, unpublished observations) and therefore likely does not
contribute significantly to metabolism of the glycosphingoid base
in the blood.
FIGURE 6 | Activity of α-galactosidases toward semi-natural and natural lipid
substrates. (A) Pure recombinant proteins were incubated with 5 µM of
NBD-C12-Gb3. detection of formation of NBD-C12Lactosylceramide, Lac
Cer detected by HPTLC. (B) Pure α-NAGALs (wild type and modified) were
incubated with 5 µM of NBD-C12-Gb3 in presence/absence of 2.5 mM
N-acetyl-galactosamine. Formation of NBD-C12-Lactosylceramide detected
by HPLC. (C) Pure plant produced galactosidases and Fabrazyme were
incubated with 5 µM of C18-Gb3, and Lyso-Gb3. Formation of Lac Cer and
Lyso-Lac Cer (pmol/h/µg) detected by LC–MS/MS. Data represent the
mean ± SD, n = 2. (D) Correction of Lyso-Gb3 in FD serum of two different
Fabry patients pre-ERT after incubation with pure plant produced enzymes
(each 8 µmol artificial 4MU-substrate hydrolysis/h/ml) overnight at 37◦C.
Lyso-Gb3 levels measured by LC–MS/MS. Data represent as mean ± SD,
n = 2. Asterisk(s) indicate significant difference as measured by a standard
Student’s t-test, ∗P < 0.05.
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CONCLUSION
We here demonstrate that production of substantial
amounts of wild type human α-GAL, α-NAGAL and
modified α-NAGALEL is feasible in N. benthamiana,
resulting in enzymes with comparable kinetic properties
to those produced in mammalian cell production systems.
The introduction of two amino acid substitutions in
α-NAGAL improves its α-galactosidase activity as measured
with artificial fluorogenic substrate and natural lipids.
A significant difference between α-GAL and α-NAGAL
is the greater stability and activity at neutral pH of the
latter enzyme. Furthermore α-NAGAL is not inhibited
by existing Ab in male FD patients by present ERTs.
Modifications in the catalytic pocket of α-NAGAL can
improve its capacity to degrade Gb3 and Lyso-Gb3. The
kinetic properties of modified α-NAGAL and its greater
stability at neutral pH could be further exploited for
treatment of FD. In particular, use of modified α-NAGAL to
reduce circulating Lyso-Gb3 in FD patients warrants further
examination.
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